The binding of endogenous retinoids and stereoisomers of retinoic add (RA) to the retinoid nuclear receptors, RA receptor (RARs) and retinoid X receptors (RXRs), was characterized using nucleosol preparations from transiently transfected COS-1 cells. Among several stereoisomers of RA tested, including 7-cis-, 9-cis-, 11-cis-, 13-cis-, and all-trns-RA, only 9-cis-RA effectively competes with 9-cis-[3HJRA binding to the RXRs. Additionally, the endogenous retinoid trans-didehydro-RA (t-ddRA) does not interact with RXRs, whereas the 9-cis form of ddRA competes effectively. RXRs (a, (, and 'y) bind 9-cts-RA with dissociation constants (Kd) of 15.7, 18.3, and 14.1 nM, respectively. In contrast to the selectivity of RXRs for 9-cis-RA, RARs bind both t-RA and 9-cis-RA with high affinity, exhibitng Kd values in the 0.2-0.7 nM range for both ligands. Unlike RARs, the cellular RA bindig proteins CRARPI or CRABPH bind t-RA but do not bind 9-cis-RA. Consistent with the binding data, 9-cis-RA and 9-cis-ddRA tnscriptionally activate both GAL4-RXR and GAL4-RAR chimeric receptors with ECso values of 3-20 nM for 9-cis-RA and 9-cis-ddRA, whereas t-RA and t-ddRA efficiently activate only GAIA-RAR chimeric receptors. Thus, 9-cis forms of en s retinoids can contribute to the pleiotropic effects of retinoids by interacting with both the RARs and RXRs.
Retinoids have a broad spectrum of biological activities in growth and differentiation of epithelia (1) , embryonic development (2) , and spermatogenesis (3) . These effects are thought to result from interactions of retinoids with nuclear receptors (4, 5) that are members of the steroid-thyroid hormone superfamily ofreceptors and as such are considered to be ligand-dependent transcription factors (6, 7) . One explanation for the diversity of retinoid action resides in the multiplicity of nuclear receptors (for a review, see ref. 8) . Two families of nuclear retinoid receptors have been described, the retinoic acid receptors (RARs) (4, 5, 9, 10) and the retinoid X receptors (RXRs) (11) (12) (13) . These two retinoid receptor families are divergent, sharing only 29%6 homology in their ligand binding domains (8, 11) , and may control in the form of RAR-RXR heterodimers the expression of RA target genes (12, (14) (15) (16) and references therein). They may also regulate separate gene pathways through distinct response elements (17, 18) . Furthermore, within the families of receptors there may be preferential activation of specific responsive promoters by the different receptor types (a, ,B, or y) (19) . This multiplicity of receptors and gene pathways may in part explain the pleiotropic effects of retinoids for the control of a wide variety of cellular processes.
Another factor controlling the pleiotropic effects of retinoids may be the existence of multiple ligand pathways for the retinoid receptors. The RARs directly bind all-trans-RA (t-RA) and as a consequence of this binding become transcriptionally active. The RXRs differ from the RARs in that they are incapable of binding t-RA, but they bind and are activated by the 9-cis stereoisomer of RA (20, 21) . The 3,4-didehydro form of t-RA (t-ddRA) is also biologically active and is found in the chicken limb (22) and in mammalian tissues (23, 24) . It is not known whether t-ddRA has a unique receptor or whether its effects are mediated by interactions with one of the RARs or RXRs.
In the present investigation, we examine the ligand specificity of the receptors and the cellular RA binding proteins (CRABPs) for RA stereoisomers and other naturally occurring retinoids. The results demonstrate that the RXRs are selective for 9-cis-RA and 9-cis-ddRA but that the RARs effectively bind and are activated by 9-cis-RA as well as t-RA. These results suggest a role for 9-cis-RA in the induction of RA target gene responses through RAR (25) containing cDNAs for mouse RARs a, f3, or y; RXRs a, ,B, or y; or CRABPI or CRABPII as described (20) . Nucleosol or cytosol fractions were prepared (26, 27) and stored at -80°C until use. Aliquots of nucleosol or cytosol were incubated in nuclei lysis buffer (26) with tritiated ligands for 4 h at 4°C. Retinoids were added in ethanolic solutions that did not exceed 2% of the total incubation volume. For competitive binding assays, the incubations were performed with increasing concentrations of unlabeled competing ligand and a fixed concentration of the radioligand (10 nM 9-cis-[3H]RA). In saturation kinetics studies, incubations were performed in the presence of increasing concentrations ofthe indicated radioligand. For all binding assays, bound was separated from free radioactivity as described (20) . Binding in the presence of a 100-fold molar excess of unlabeled ligand was defined as nonspecific bindAbbreviations: RA, retinoic acid; dd, 3,4-didehydro; t, all-trans; RAR, RA receptor; RXR, retinoid X receptor; CRABP, cellular RA binding protein; CAT, chloramphenicol acetyltransferase. §To whom reprint requests should be addressed. 30 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
ing. Specific binding was defined as total binding minus nonspecific binding.
The concentration required to produce a 50% inhibition of binding (IC50) was calculated from competition data (28) . Saturation kinetics data were analyzed as described (20, 29, 30) .
Chimeric Receptors and Transactivation Assays. GAL4-RAR a, 13, and y chimeras were constructed by PCR amplification of the D to F regions of mouse RAR a, 13, and y (31) to give DNA fragments with a 5' Xho I site and a 3' Kpn I site that were subcloned into the expression vector pGAL4(1-147)ER region F (32) . The encoded chimeric GAL4-RAR proteins, therefore, consist of GAL4 amino acids 1-147, a short linker region encoding amino acids IGRPPRA, followed by the RAR DEF regions linked to region F of human estrogen receptor amino acids 553-595 by 2 amino acids (GT), corresponding to the Kpn I site (see Fig. 4 ). The GAL4-RXR a, f3, and y chimeras were constructed by PCR amplification of the DE regions of mouse RXR a, 13, and y (12), followed by subcloning into GAL4MpolyII (33) . The linker region joining the GAL4 DNA binding region to RXR sequences encodes the amino acids IPRA (see Fig. 4 ). The chimeric constructs were verified by DNA sequence analysis and Western blot analysis after expression in transiently transfected COS-1 cells.
HeLa cells were transfected as described (33) with 50 ng of a given GAL4 chimera, 500 ng of the reporter gene 17M/ ERE-G.CAT, 2 ,ug of pCH110, and 12.5 1ug of BSM13+ as carrier. Twenty-four hours after transfection, cells were treated for 12-15 h with various concentrations of t-RA, 9-cis-RA, t-ddRA, or 9-cis-ddRA as indicated. The relatively short treatment with ligand was to minimize isomerization of RA or ddRA (20) . Chloramphenicol acetyltransferase (CAT) activity was determined as described after correction for variations in transfection efficiency (33) .
RESULTS
We have previously demonstrated (20) that when COS-1 cells are cultured for 48 h with t-RA, the nuclei, enriched by transfection with RXRs, selectively trap 9-cis-RA. This stereoisomer binds RXRs directly and activates these receptors (20, 21) , suggesting a role for stereoisomers of RA in defining ligand pathways for retinoids. To determine whether other stereoisomers of RA are ligands for the RXRs, competitive binding assays were performed under equilibrium conditions in which binding was proportional to nucleosol concentration and remained constant from 5 min to 16 h ofincubation (G.A., unpublished data).
The 7-cis and 13-cis isomers of RA produce little or no inhibition of 9-cis-[3H]RA binding to the RXRs so that IC50
values for these compounds are greater than the maximum concentrations of 50,000 nM tested. The li-cis isomer of RA inhibits the binding of 9-cis-[3H]RA to the RXRs, but the inhibition is weak and the concentrations required to produce a 50% inhibition ofbinding are in the range of5000-12,000 nM (20, 21) .
Because 9-cis-RA had been shown to activate both RXRa and RARa (21), we sought to determine whether 9-cis-RA directly bound to RARs. Interestingly, we found that 9-cis-RA binds to RARs with high affinity. (Fig. 2) , indicating that the affinities for the binding of 9-cis-RA to RARs are at least 20-fold higher than those for the binding of 9-cis-RA to RXRs ( Table 2 ). The human RARs bind 9-cis-RA with high affinities similar to those reported here for the mouse receptors (G.A., unpublished data). When the Kd values for the binding of t-RA and 9-cis-RA to mouse RARs are compared ( Thus, in contrast to the RARs, which bind both 9-cis-RA and t-RA with approximately equal affinities, CRABPI and CRABPII bind t-RA but not 9-cis-RA (Fig. 3) . These data do not exclude the possibility that CRABPs may bind 9-cis-RA with very low affinity (B. P. Sani, J.F.G., and A.A.L., unpublished results).
To determine whether the binding specificity of the RXRs for 9-cis-RA and the apparent high affinity of the RARs for 9-cis-RA were correlated with transcriptional activation of the receptors, chimeric receptors were employed to limit the interference from endogenous retinoid receptors. Chimeric receptors contained the DNA binding domain of the yeast transactivator GAL4 [GAL4-(1-147)] fused to the C-terminal Fig. 4) .
These chimeras bind efficiently as homodimers to a 17-mer GAL4 response element to which endogenous retinoid receptors cannot bind (M.S., unpublished results). Cotransfection of HeLa cells with a given GAL4-RXR or GAL4-RAR chimera and the 17M/ERE-G.CAT reporter gene (33) results in a retinoid-concentration-dependent increase of CAT activity. For all three RXR chimeras, 9-cis-RA is much more efficient than either t-RA or t-ddRA at activating transcription from the reporter gene (Fig. 5 A-C) . The EC56 values for activation by 9-cis-RA are 7 nM for GAL4-RXRa, 20 nM for GAL4-RXR(3, and 10 nM for GAL4-RXR'y. In all three cases, t-RA and t-ddRA are much less potent than 9-cis-RA, and no significant activation is seen at 10 nM. Of particular interest, the 9-cis stereoisomer of ddRA (9-cis-ddRA) activates the three GAL4-RXR chimeras with EC50 values similar to those of 9-cis-RA (M.-T.B., unpublished data). Clearly the 9-cis forms of RA and ddRA are active Zgands for the RXRs exhibiting a good correlation between binding and transactivation.
The high affinity of 9-cis-RA for the RARs in binding assays suggested that 9-cis-RA should be a potent activator of these receptors. In fact, 9-cis-RA activates the RARs at least as potently as t-RA. Additionally, t-RA, t-ddRA, 9-cis-RA, and 9-cis-ddRA have very similar effects (Fig. SD-F and data not shown). The 50%o maximal response values for 9-cis-RA (or 9-cis-ddRA) and t-RA (or t-ddRA) are 10 nM and priate reporter were transiently transfected into HeLa cells. For the GAL4-RXR chimeras, maximal activity in the presence of 9-cis-RA was taken as 100%, whereas for the GAL4-RAR chimeras, 100%o CAT activity corresponded to the maximal activity produced by t-RA. 100 nM for GAL4-RARa, 3 nM and 5 nM for GAL4-RAR,8, and 20 nM and 6 nM for GAL4-RARy, respectively. GAL4-RARa and GAL4-RAR/B are more efficiently activated by 9-cis-RA or 9-cis-ddRA than by t-RA or t-ddRA at all ligand concentrations. In contrast, while 9-cis-RA (or 9-cis-ddRA) is less potent than t-RA in activating GAL4-RARy, it exhibits a greater efficacy in that it induces a stronger maximal response (Fig. 5 D-F) . These data confirm the binding data, which indicate that the affinity of RARy for 9-cis-RA is lower than for t-RA.
While there was a good correlation in the data for 9-cis-RA binding and transactivation in the case of RXRs, there was a notable lack of correlation between binding affinities and EC50 values for transactivation in the case of RARs (Table 2 and Fig. 5 ). The binding affinities of RARs for 9-cis-RA and t-RA are in the range of 0.2-0.7 nM (Table 2 ), yet the EC50 values for transcriptional activation are in the range of 3-100 nM (Fig. 5) . Previous studies on RA-induced transcriptional activation of wild-type RARs (21, 38) and other RAR chimeras (39) have yielded similar EC50 values; thus the difference in Kd and EC50 values does not appear to be related to the GAL4 chimeras employed here. The magnitude of this discrepancy is most profound with RARa and corresponds to a two order of magnitude difference between binding and transactivation data. At this time, we do not understand the molecular basis for this difference. One interesting possibility (S. Nagpal and P.C., unpublished data) might be that, within HeLa cells, GAL4-RARa heterodimerizes with RXRs. Conceivably, this heterodimer may bind and be activated better by 9-cis-RA than t-RA. This would suggest that the low potency of t-RA activation of GAL4-RARa reported here may depend on its conversion to 9-cis-RA. Such an explanation might account for the difficulty in reaching a maximum response with RARa by using t-RA (Fig. 5D , and see ref. 21 ).
DISCUSSION
We extended our previous observation that 9-cis-RA is an endogenous ligand for RXRa (20) by demonstrating that 9-cis forms of the endogenous retinoids RA and ddRA bind to RXRs a, /3, and y with relatively high affinities. RXRs are remarkably selective in that they do not bind the trans forms of RA and ddRA, nor do they bind other stereoisomers of RA including 7-cis-, 11-cis-, and 13-cis-RA. These data clearly indicate that the 9-cis conformation is essential for the biological activity mediated by RXRs. An unexpected result from these experiments is that 9-cis forms of RA and ddRA can also strongly interact with the RARs. Scatchard analyses demonstrate that 9-cis-RA and t-RA bind to RARs with similar high affinities. Additionally, we demonstrate that 9-cis-RA activates all three RARs with high potency. In fact, 9-cis-RA is more potent than t-RA for activating RARa and RAR/3 chimeric constructs. The RARy construct was somewhat different in that t-RA yielded a slightly lower EC50
value, but 9-cis-RA induced a greater maximum response. Thus the 9-cis conformation of the endogenous retinoids tested appears to be important for the activity of both families of retinoid receptors, RXRs and RARs. We propose that 9-cis forms of endogenous retinoids are the cognate ligands that activate RXR-mediated pathways. However, if we consider RAR-mediated activity, our data suggest that both the trans and the 9-cis forms can function as active ligands.
Recent data indicate that the RXRs form heterodimers with RARs and other receptors in the steroid/thyroid superfamily. Additionally, the RXRs coregulate the activity of RARs on their response elements (see the Introduction for references). RAR-RXR heterodimers are interesting protein complexes in relation to the observation that endogenous 9-cis-retinoids can bind both RARs and RXRs. We can speculate that there would exist a number of ligand-receptor interactions involving both t-RA and 9-cis-RA. For example, the ligand binding domains within an RAR-RXR heterodimer could be occupied by only 9-cis-RA or by both 9-cis-RA and t-RA. Binding assays presented here were performed under conditions that favor monomers of RAR (26) . Under these conditions, we find that 9-cis-RA binds to the RARs with an =20-fold greater affinity -than to the RXRs. If the RXR-RAR heterodimers bind 9-cis-RA in a similar fashion, then we would expect that 9-cis-RA would compete with t-RA for binding to this complex. However, it is possible that heterodimerization can alter receptor binding affinities because the dimerization domain of these receptors overlaps with the ligand binding domain (12, 14) .
One interesting question that arises from these data concerns the availability of 9-cis-RA at its cellular site of action. The concentration oft-RA in tissues and serum is in the range of 5-10 nM (2, 40, 41) . The available data indicate that the 9-cis-RA concentrations were 3-fold lower than available t-RA concentrations in several tissues (21) , which suggests that 9-cis-RA concentrations would be in the low nanomolar range. According to the data reported here, these levels are lower than the Kd values for the binding of9-cis-RA to RXRs, but they are in the range of the Kd values for the binding of 9-cis-RA to RARs. However, recent data indicate that nanomolar concentrations of 9-cis-RA promote RXR homodimer formation, leading to the activation of several response elements (42) . Conceivably, the binding properties of receptors in whole cells may differ from those of receptors in our nucleosol preparations yielding Kd values more in the range of the endogenous concentrations of 9-cis-RA.
Synthesis of t-RA from retinol has been implicated as one factor in controlling t-RA concentration (43) (44) (45) , but the source of 9-cis-RA is less clear. Isomerization from t-RA is a possible route, or 9-cis-retinol precursors in tissues (46) (47) (48) may be oxidized. Another factor is the presence of CRABPs in the cell. The CRABPs are thought to control the levels of free t-RA by sequestration (35) and may play a role in the degradation of t-RA by microsomal enzymes (36, 37) . We have shown that 9-cis-RA does not bind to the CRABPs.
Proc. Nadl. Acad. Sci. USA 90 (1993) CRABP binding may directly modulate the concentration of free t-RA, but not that of 9-cis-RA. However, if 9-cis-RA is a product of the isomerization of t-RA, then CRABPs could indirectly control the level of 9-cis-RA.
We have demonstrated that there is an intricate pattern of endogenous RA interactions with the nuclear retinoid receptors and CRABPs. This ligand pattern combined with the multiplicity of receptor types and isoforms (8, 49) and the differential transactivation of RA responsive promoters by these receptors (19) yield a system with sufficient combinatorial factors to explain retinoid control ofcomplex biological processes (for further discussion, see ref. 8 ).
